×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Liver Cancer

Jessica Skarzynski
With a wealth of drugs available for the treatment of liver cancer, one expert explained how combination therapy may be where the future is headed.
Matthew Loxton
Blue Faery provides patients with hepatocellular carcinoma and their caregivers a range of focused resources. The goal of Blue Faery’s patient community is to improve the quality of life for patients, support their caregivers and give them hope, information and a voice.
Jessica Skarzynski
The president and founder of Blue Faery: The Adrienne Wilson Liver Cancer Association discussed new initiatives and what’s on the horizon in the treatment of liver cancer.
Kristie L. Kahl
While advances have been made in the treatment landscape of hepatocellular carcinoma, researchers are now looking into the optimal sequence for which patients should be treated.
Andrea Wilson
Andrea Wilson, president and founder of Blue Faery: The Adrienne Wilson Liver Cancer Association, spoke with CURE® at the 2019 ASCO meeting about the loss of her sister and how it inspired her to found Blue Faery.
 
Alexandra Guadagno
The combination use of Abraxane plus gemcitabine and cisplatin for the treatment of advanced biliary tract cancers prolonged survival, according to phase 2 study findings.
Beth Fand Incollingo
Through community outreach, the Cholangiocarcinoma Foundation aims to increase tumor profiling and clinical trial participation.
Brielle Benyon
The Food and Drug Administration approved Cyramza for certain patients with hepatocellular carcinoma.
Kristie L. Kahl
Because of the rarity of a neuroendocrine tumor (NET) diagnosis, the Healing Net Foundation aims to educate physicians on the disease – an initiative many patient advocates feel can improve outcomes.
Katie Kosko
A Taiwanese study compares disease rates among people who used the medication daily with those who do not.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×